Jinxin Fertility Signals Sharp Profit Turnaround on Recovery in Core Markets
I'm LongbridgeAI, I can summarize articles.Jinxin Fertility Group (HK:1951) forecasts a sharp profit turnaround, swinging from a RMB1.04 billion loss in H1 2025 to at least RMB90 million net profit in H1 2026. Driven by recovering U.S. operations and increased demand for assisted reproductive treatments in China, the company also projects EBITDA of no less than RMB290 million. Analysts maintain a 'Buy' rating with a HK$3.80 price target.
Jinxin Fertility Group Ltd. ( (HK:1951) ) has provided an announcement.
Jinxin Fertility Group Limited has issued a positive profit alert, forecasting a swing from a net loss of about RMB1.04 billion in the first half of 2025 to a net profit of at least RMB90 million in the first half of 2026. The group also expects EBITDA of no less than RMB290 million and adjusted net profit of at least RMB120 million, marking a sharp operational recovery.
Management attributes the improvement to a rebound in its U.S. fertility business, greater uptake of personalized VIP services and broader adoption of assisted reproductive treatments in China, together lifting patient volumes. The turnaround is further supported by the absence of large impairment charges and other one-off items that weighed on the prior-year results, signaling a cleaner earnings base but still subject to final audit and investor caution.
The most recent analyst rating on (HK:1951) stock is a Buy
with a HK$3.80 price target.
To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock,
see the HK:1951 Stock Forecast page.
More about Jinxin Fertility Group Ltd.
Jinxin Fertility Group Limited operates in the assisted reproductive services and fertility healthcare industry, offering in-vitro fertilization and related treatments across China and the United States. The group focuses on expanding personalized, VIP-oriented fertility services and capitalizing on rising demand for infertility treatment, particularly amid wider adoption of assisted reproductive technologies in its core markets.
The company’s U.S. operations have been recovering, driving higher oocyte pick-up cycle volumes, while its Chinese clinics benefit from increasing new patient visits for infertility services. This positioning supports Jinxin Fertility’s strategy to grow through premium service offerings and international exposure in a specialized, high-growth segment of the healthcare sector.
Average Trading Volume: 13,959,868
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.87B